A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

NCT00479167 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual and interest in study

Conditions

Follicular Lymphoma

Interventions

DRUG: Bortezomib and Tositumomab I-131

Sponsor

Rush University Medical Center

Collaborators

[object Object]
[object Object]